These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23883384)

  • 1. Mapping the journey to an HIV vaccine.
    Ackerman M; Alter G
    N Engl J Med; 2013 Jul; 369(4):389-91. PubMed ID: 23883384
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 3. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 5. A pathway to HIV-1 neutralization breadth.
    Smith SA; Derdeyn CA
    Nat Med; 2015 Nov; 21(11):1246-7. PubMed ID: 26540383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccine design: the neutralizing antibody conundrum.
    Stamatatos L
    Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccines to antibodies: grow up!
    von Bubnoff A
    IAVI Rep; 2010; 14(4):4-9. PubMed ID: 20857647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV: Roadmaps to a vaccine.
    Mouquet H; Nussenzweig MC
    Nature; 2013 Apr; 496(7446):441-2. PubMed ID: 23552894
    [No Abstract]   [Full Text] [Related]  

  • 11. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectious disease. An enterprising time for HIV vaccine research.
    Cohen J
    Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel adjuvants for B cell immune responses.
    Loré K; Karlsson Hedestam GB
    Curr Opin HIV AIDS; 2009 Sep; 4(5):441-6. PubMed ID: 20048709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.
    Luo Z; Ren L; Zheng Y; Qi Z; Liang H; Liu Y; Hong K; Shao Y
    Vaccine; 2012 Aug; 30(36):5316-23. PubMed ID: 22749599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 19. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.